Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin.

IF 2.4 Q2 DERMATOLOGY

Current Dermatology Reports Pub Date : 2022-01-01 DOI:10.1007/s13671-022-00370-9

Rhea Singh, Esther E Freeman

{"title":"Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin.","authors":"Rhea Singh, Esther E Freeman","doi":"10.1007/s13671-022-00370-9","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review aims to evaluate the spectrum of cutaneous reactions after both SARS-CoV-2 infection and COVID-19 vaccination while simultaneously understanding the evolution of the field of dermatology in the face of an ongoing pandemic.Recent findings: The most commonly reported cutaneous reactions after COVID-19 infection in the literature to date include morbilliform or maculopapular rashes, chilblains, and urticaria. The incidence of cutaneous reactions after COVID-19 vaccination was 9% in larger cohort studies and more commonly occurred after mRNA-based COVID-19 vaccines than adenovirus vector vaccines. The most frequently reported cutaneous reactions after COVID-19 vaccines were delayed large local reactions, local injection site reactions, urticarial eruptions, and morbilliform eruptions.Summary: With the ongoing pandemic, and continued development of new COVID-19 variants and vaccines, the landscape of cutaneous reactions continues to rapidly evolve. Dermatologists have an important role in evaluating skin manifestations of the virus, as well as discussion and promoting COVID-19 vaccination for their patients.","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"11 4","pages":"289-312"},"PeriodicalIF":2.4000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574791/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13671-022-00370-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose of review: This review aims to evaluate the spectrum of cutaneous reactions after both SARS-CoV-2 infection and COVID-19 vaccination while simultaneously understanding the evolution of the field of dermatology in the face of an ongoing pandemic.

Recent findings: The most commonly reported cutaneous reactions after COVID-19 infection in the literature to date include morbilliform or maculopapular rashes, chilblains, and urticaria. The incidence of cutaneous reactions after COVID-19 vaccination was 9% in larger cohort studies and more commonly occurred after mRNA-based COVID-19 vaccines than adenovirus vector vaccines. The most frequently reported cutaneous reactions after COVID-19 vaccines were delayed large local reactions, local injection site reactions, urticarial eruptions, and morbilliform eruptions.

Summary: With the ongoing pandemic, and continued development of new COVID-19 variants and vaccines, the landscape of cutaneous reactions continues to rapidly evolve. Dermatologists have an important role in evaluating skin manifestations of the virus, as well as discussion and promoting COVID-19 vaccination for their patients.

查看原文本刊更多论文

病毒、变异和疫苗:COVID-19如何改变了我们看待皮肤的方式。

综述目的:本综述旨在评估SARS-CoV-2感染和COVID-19疫苗接种后的皮肤反应谱，同时了解面对持续大流行的皮肤病学领域的演变。最新发现:迄今为止，文献中报道的COVID-19感染后最常见的皮肤反应包括麻疹或黄斑丘疹、冻疮和荨麻疹。在大型队列研究中，COVID-19疫苗接种后皮肤反应的发生率为9%，并且基于mrna的COVID-19疫苗比腺病毒载体疫苗更常发生。COVID-19疫苗接种后最常见的皮肤反应是迟发性大面积局部反应、局部注射部位反应、荨麻疹疹和麻疹样疹。总结:随着疫情的持续，以及COVID-19新变体和疫苗的不断开发，皮肤反应的情况继续迅速发展。皮肤科医生在评估病毒的皮肤表现，以及讨论和促进患者接种COVID-19疫苗方面发挥着重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Dermatology Reports DERMATOLOGY-

CiteScore

3.30

自引率

6.20%

发文量

期刊介绍： This journal intends to review the most significant recent developments in the field of dermatology. By providing clear, insightful, balanced contributions by expert international authors, the journal aims to serve all those involved in the diagnosis, treatment, management, and prevention of dermatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field, such as epidemiology, surgery, pharmacology, clinical trial design, and pediatrics. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known figures in the field, and an Editorial Board of more than 20 internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.